2018
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Godellas C, Chen M, Kalinsky K, Hibshoosh H, Killelea B, Sanft T, Hirst G, Asare S, Matthews J, Perlmutter J, Esserman L, and I-SPY 2 Investigators. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. Npj Breast Cancer 2018, 4: 26. PMID: 30131975, PMCID: PMC6098077, DOI: 10.1038/s41523-018-0074-6.Peer-Reviewed Original ResearchAxillary lymph node dissectionLymph node dissectionClinical trialsNeoadjuvant chemotherapyNode dissectionPositive diseaseDrug therapy trialsI-SPY2 trialManagement of axillaBreast cancer clinical trialsNode-positive diseaseProspective clinical trialsMulticenter clinical trialAssessment of responseClinical trial dataCancer clinical trialsNeoadjuvant settingPrimary endpointNodal involvementSurgical resectionSurgical managementProper stagingResidual diseaseSurgical standardAxilla
2016
Recent Updates in the Management of Triple Negative Breast Cancer
Sanft T, Moran M. Recent Updates in the Management of Triple Negative Breast Cancer. TouchREVIEWS In Oncology & Haematology 2016, 12: 36. DOI: 10.17925/ohr.2016.12.01.36.Peer-Reviewed Original ResearchTriple-negative breast cancerNegative breast cancerBreast cancerLocoregional treatment optionsComplete pathologic responseNeoadjuvant chemotherapyPathologic responseResidual diseaseTreatment optionsAggressive subtypeNew agentsCancerDruggable targetsDisease biologyRecent updatesFurther researchChemotherapyPatientsTherapySubtypesDisease